Maxwell Targets $500B Cosmetics Market with Microbiome-Friendly Antiseptics
Austin, Texas--(Newsfile Corp. - June 11, 2025) - Maxwell Biosciences, an innovator in technology that behaves like the natural immune system, announces its strategic entry into partnerships and licensing deals in the cosmetics and personal care market with its immune-inspired Claromer™ platform. The company's breakthrough Claromer™ technology is now being tested by some of the top cosmetics companies in the world. Maxwell aims to usher in a new generation of personal care products designed for today's health-conscious consumer.
2025-06-11 12:00 PM EDT
Maxwell Biosciences Secures Anti-Diarrheal US Military Agreement
Austin, Texas--(Newsfile Corp. - April 23, 2025) - Maxwell Biosciences, a preclinical drug platform company that develops ClaromersTM, synthetic small molecules that mimic and improve upon the natural immune system, today announced a new collaboration. Maxwell has entered into a Limited Purpose Cooperative Research and Development Agreement (LP-CRADA) with the U.S. Naval Medical Research Command's (NMRC) Deployment Associated Infections Division (DAID) laboratory to conduct in vitro testing of Claromers™ for treatment and prevention of diarrheal illness. This agreement marks the...
2025-04-23 9:00 AM EDT
Maxwell Biosciences Secures US Military Agreement to Research Scientific Aspects of Claromer Technology
Austin, Texas--(Newsfile Corp. - March 5, 2025) - Maxwell Biosciences, a preclinical drug platform company that develops ClaromersTM, synthetic small molecules that mimic and improve upon the natural immune system, today announced a new collaboration. Maxwell has entered into a Cooperative Research and Development Agreement with the U.S. Army Institute of Surgical Research (USAISR). Using their research experience and resources, the U.S. Army will conduct studies to support development of Maxwell's therapeutics that will treat viral, bacterial and fungal threats....
2025-03-05 9:00 AM EST
Maxwell Biosciences Secures US Military Research Agreement to Combat Dengue Fever
Austin, Texas--(Newsfile Corp. - February 26, 2025) - Maxwell Biosciences, a preclinical drug platform company that develops ClaromersTM, synthetic small molecules that mimic and improve upon the compounds of the human immune system, today announced a new collaboration. Maxwell has entered into a Cooperative Research and Development Agreement to develop therapies for dengue virus infections with the Naval Medical Research Command's (NMRC) Naval Medical Infectious Diseases Diagnostic Laboratory (NIDDL).
2025-02-26 9:00 AM EST
Maxwell Biosciences Announces Appointment of José Antonio Alas to Its Board of Directors
Austin, Texas--(Newsfile Corp. - January 22, 2025) - Maxwell Biosciences ("Maxwell"), a pre-clinical drug platform company that develops Claromers™, synthetic small molecules that mimic and improve upon natural immune system peptides, today announced the appointment of José Antonio Alas to its Board of Directors. The appointment adds a seasoned industry veteran with extensive international market expertise to Maxwell. "Antonio's heart is in the right place and his experience in public-private partnerships with many governments will elevate our capabilities to...
2025-01-22 9:00 AM EST
Maxwell Biosciences Selected to Receive a Nearly $3M Award from Medical Technology Enterprise Consortium (MTEC)
Austin, Texas--(Newsfile Corp. - October 24, 2024) - Maxwell Biosciences is developing a new type of anti-infective drug designed to improve upon natural immune system peptides. The company announced today it has been selected to receive a nearly $3M award from the Medical Technology Enterprise Consortium (MTEC). MTEC works in cooperation with the U.S. Army Medical Research and Development Command (USAMRDC) and the U.S. Department of Defense. Maxwell received this award for its proposal titled "Pathogen-Agnostic Claromer® Prophylactic to Prevent...
2024-10-24 9:00 AM EDT
Maxwell Biosciences CEO J. Scotch McClure Named Top 25 Executive in Biotechnology
Austin, Texas--(Newsfile Corp. - May 15, 2024) - Maxwell Biosciences, Inc, a pre-clinical drug platform company focused on developing biomimetic therapeutics that improve upon natural immune system peptides, today announced that its Chief Executive Officer J. Scotch McClure was named to The Healthcare Technology Report's list of the Top 25 Executives in Biotechnology for 2024. The annual list recognizes the most accomplished executives in the biotech industry.Selections were based on nomination submissions as well as research on industry leading companies...
2024-05-15 11:45 AM EDT
Maxwell Biosciences Enters Second CRADA with USAMRIID to Test Claromer Compounds as Potential Therapeutics for Viral and Bacterial Pathogens
Austin, Texas--(Newsfile Corp. - May 8, 2024) - Maxwell Biosciences, a preclinical drug platform company focused on developing biomimetic therapeutics that improve upon natural immune system peptides based on its patented Claromer® technology platform, today announced that they have entered into a second Cooperative Research and Development Agreement (CRADA) with the United States Army Medical Research Institute of Infectious Diseases (U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID)). Part of the U.S. Army Medical Research and Development Command, USAMRIID...
2024-05-08 11:45 AM EDT
Maxwell Biosciences Announces Promising Activity of Claromer Compound Against Ebola Virus in a Research Study
Austin, Texas--(Newsfile Corp. - November 2, 2023) - Maxwell Biosciences, Inc., (MXB) a pre-clinical drug platform company focused on developing biomimetic therapeutics that improve upon natural immune system peptides based on its patented Claromer® technology platform, today announced that it has received promising data on activity against Ebola virus from a study conducted in collaboration with NIH-NIAID's Rocky Mountain Laboratories (RML). RML is one of the few Biosafety Level (BSL) 4 labs in the United States with the capability to...
2023-11-02 11:00 AM EDT
Maxwell Biosciences Enters CRADA with USAMRIID to Test Claromer Compounds as Potential Therapeutics for Viral Pathogens, Including Hemorrhagic Fever Ebola Viral Disease, and Other Biodefense Pathogens
Austin, Texas--(Newsfile Corp. - October 25, 2023) - Maxwell Biosciences, a pre-clinical drug platform company focused on developing biomimetic therapeutics that improve upon natural immune system peptides based on its patented Claromer® technology platform, today announced that they have entered into a Cooperative Research and Development Agreement (CRADA) with the United States Army Medical Research Institute of Infectious Diseases (U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID)). Part of the U.S. Army Medical Research and Development Command, USAMRIID is...
2023-10-25 10:00 AM EDT
Maxwell Biosciences Appoints Major General (Ret.) Barb Holcomb, RN, BSN, MSN to Its Board of Directors
Austin, Texas--(Newsfile Corp. - October 18, 2023) - Maxwell Biosciences ("Maxwell"), a preclinical drug platform company developing a synthetic immune system that may serve as a key biodefense asset, today announced the appointment of Major General (Retired) Barb Holcomb, RN, BSN, MSN to its Board of Directors. This appointment adds one of the world's top national security and biodefense research and logistics executives to Maxwell's board.General Holcomb's leadership is instrumental in connecting Maxwell with biodefense experts in the US Department...
2023-10-18 2:16 PM EDT
Maxwell Biosciences Announces Publication of Mechanism of Action Study: Claromer Compounds Target Pathogens by Disrupting Their Membranes
Austin, Texas--(Newsfile Corp. - August 2, 2023) - Maxwell Biosciences, a pioneering preclinical drug platform company, today announced publication of a revolutionary mechanism of action study for their Claromer® compounds in the journal ACS Infectious Diseases.In this study, the researchers showed how a group of novel molecules - inspired by the human immune system - inactivates several viruses, including all tested Influenza, Coronavirus, Hepatitis, Herpes, Zika and Chikungunya strains. Their approach may lead to drugs that can be used against...
2023-08-02 1:54 PM EDT
Biotech Startup Maxwell Biosciences Selected to Present at the Angel Capital Association 2023 Summit
Austin, Texas--(Newsfile Corp. - May 11, 2023) - The Angel Capital Association (ACA) will host "ACA 2023 - The Summit of Angel Investing" (ACA Summit) from May 16-18 in Las Vegas. The flagship angel investing event of the year will bring together angel investors from across North America to learn from industry experts and network with a diverse investor community to support better investment decisions.During the ACA's Innovation Funders Showcase, Maxwell Biosciences (Maxwell), a preclinical drug discovery platform company,...
2023-05-11 11:00 AM EDT
Maxwell Biosciences Announces the Appointment of Maxie McFarland, MBA, as Senior Vice President of Corporate Development and Investor Relations
Austin, Texas--(Newsfile Corp. - April 25, 2023) - Maxwell Biosciences ("Maxwell"), a preclinical drug discovery platform company focused on the development of synthetic compounds that mimic existing human biomolecules (biomimetic therapeutics) from our innate immune system, today announced the appointment of Maxie McFarland, MBA, as Senior Vice President of Corporate Development and Investor Relations. Maxie brings more than 20 years of diverse experience in corporate development and strategy."We are pleased to welcome Maxie to Maxwell Biosciences," said Maxwell CEO and...
2023-04-25 10:00 AM EDT